Evotec week opens with drug discovery focus, shares on Frankfurt
29.06.2026 - 20:19:04 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 20:18.
Evotec SE (DE0005664809) begins the new trading week with its core business model in focus. The Hamburg-based biotech company is listed on the Frankfurt exchange and acts as a discovery and development partner for large pharmaceutical groups.
Evotec work with big pharma
Evotec SE positions itself as a contract research and development organization, providing discovery platforms and early-stage development services to pharmaceutical and biotech clients such as Bayer and Bristol Myers Squibb. The group specializes in identifying and optimizing small-molecule and biologic drug candidates for a range of therapeutic areas.
Through long-term collaborations, Evotec SE shares project risk with partners while earning research payments, milestones and potential royalties on successful drug candidates. This model aims to generate a diversified pipeline of partnered programs without Evotec bearing the full cost of late-stage clinical trials.
Biotech peers in Europe
On the Frankfurt exchange, Evotec SE is part of the German and European biotech sector, alongside companies such as Morphosys and Qiagen. Investors often compare Evotec SE to these peers in terms of pipeline breadth, partnership quality and balance between service revenues and success-based milestone income.
In the broader European context, Evotec SE competes with other contract research and discovery-focused firms, including UK-listed Horizon Discovery and French group Innate Pharma, reflecting a fragmented but growing market for outsourced R&D services in life sciences.
All news and analysis on the Evotec SE shares
More updates, filings and commentary about Evotec SE shares and its biotech partnerships can be found on the dedicated ad-hoc-news topic page and the company's Investor Relations site.
The product behind the stock
Evotec SE generates most of its revenue by providing integrated drug discovery and development services rather than selling a single flagship product. Clients use Evotec SE platforms for target identification, hit finding, lead optimization and early clinical development, paying for access to its scientific teams and technologies.
Where the stock trades today
Evotec SE shares trade on the Frankfurt exchange, providing investors with exposure to the European biotech and contract research segment through a Germany-listed stock, but current intraday price data is not included in this article.
Evotec SE at a glance
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVO
- Trading venue: Frankfurt
- Price (as of 2026-06-29, 18:00): [price] EUR
- Market cap: [market cap] EUR (as of 2026-06-29)
- Sector / industry: Biotechnology / Life Sciences
- Index membership: not part of a major blue-chip index
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
